According to filings with the U.S. Securities and Exchange Commission, PROBIUSDX is raising up to $25,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About PROBIUSDX
Probius, is a deep-tech company bridging the data gap between biology and AI, thereby illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products .

To learn more about PROBIUSDX, visit https://www.probius.bio/
PROBIUSDX Linkedin Page: https://www.linkedin.com/company/probius/

Contact:
Emmanuel Quevy, Chief Executive Officer
888-615-1825
https://www.linkedin.com/in/emmanuelquevy/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.